JP2017528129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528129A5 JP2017528129A5 JP2017510624A JP2017510624A JP2017528129A5 JP 2017528129 A5 JP2017528129 A5 JP 2017528129A5 JP 2017510624 A JP2017510624 A JP 2017510624A JP 2017510624 A JP2017510624 A JP 2017510624A JP 2017528129 A5 JP2017528129 A5 JP 2017528129A5
- Authority
- JP
- Japan
- Prior art keywords
- nmi
- ifp35
- seq
- activity
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010050685 Cytokine storm Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 206010052015 cytokine release syndrome Diseases 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 claims 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 238000006384 oligomerization reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410418773 | 2014-08-22 | ||
| CN201410418773.1 | 2014-08-22 | ||
| PCT/CN2015/000602 WO2016026258A1 (en) | 2014-08-22 | 2015-08-21 | Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528129A JP2017528129A (ja) | 2017-09-28 |
| JP2017528129A5 true JP2017528129A5 (enExample) | 2018-10-04 |
| JP6968696B2 JP6968696B2 (ja) | 2021-11-17 |
Family
ID=55350147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510624A Active JP6968696B2 (ja) | 2014-08-22 | 2015-08-21 | 異常なレベル及び／又は活性のｉｆｐ３５ファミリーのタンパク質に関連する疾患又は障害を治療及び／又は予防するための方法及び組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US11466061B2 (enExample) |
| EP (1) | EP3182990A4 (enExample) |
| JP (1) | JP6968696B2 (enExample) |
| CN (3) | CN115054687A (enExample) |
| WO (1) | WO2016026258A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466061B2 (en) | 2014-08-22 | 2022-10-11 | Yingfang Liu | Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the IFP35 family of proteins |
| JP7475366B2 (ja) * | 2019-04-01 | 2024-04-26 | 広州恩邁生物科技有限公司 | 慢性炎症およびウイルス感染の診断と治療 |
| CN110669765B (zh) * | 2019-11-04 | 2022-11-01 | 中国科学院水生生物研究所 | 鳜干扰素诱导蛋白启动子和应用 |
| CN113234153B (zh) * | 2021-04-07 | 2022-12-20 | 中山大学 | 一批识别ifp35家族蛋白的单克隆抗体及其在免疫识别等方面的应用 |
| CN118667940A (zh) * | 2021-07-09 | 2024-09-20 | 广州恩迈生物科技有限公司 | Ifp35和/或nmi在诊治银屑病中的应用 |
| CN116239685A (zh) * | 2023-02-24 | 2023-06-09 | 中山大学·深圳 | 一种识别ifp35蛋白的抗体及其应用 |
| KR20250162870A (ko) * | 2023-04-10 | 2025-11-19 | 광저우 언마이 바이오테크놀로지 컴퍼니 리미티드 | 항-nmi 단클론 항체 또는 이의 항원 결합 단편 및 이의 응용 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489136B1 (en) * | 1997-05-09 | 2002-12-03 | The General Hospital Corporation | Cell proliferation related genes |
| EP0921192A1 (en) * | 1997-12-03 | 1999-06-09 | Leadd B.V. | Molecules interacting with apoptin |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| TW200413539A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Genes and polypeptides relating to prostate cancers |
| JP2008518626A (ja) * | 2004-11-05 | 2008-06-05 | アメリカ合衆国 | 血中で宿主遺伝子発現バイオマーカーを使用する感染症臨床表現型及びその他の生理学的状態の診断及び予後 |
| BRPI0616656A2 (pt) * | 2005-10-03 | 2011-06-28 | Novartis Ag | ativador de membrana conservada de calcineurina (cmac), uma proteìna terapêutica e alvo |
| FR2892730A1 (fr) * | 2005-10-28 | 2007-05-04 | Biomerieux Sa | Methode pour detecter la presence ou le risque de developper un cancer |
| JP5784272B2 (ja) * | 2006-04-24 | 2015-09-24 | ジェネンテック， インコーポレイテッド | 自己免疫性疾患を検出するための方法及び組成物 |
| CA2650616A1 (en) * | 2006-04-26 | 2007-11-08 | Vertex Pharmaceuticals Incorporated | Hepatitis c virus infection biomarkers |
| KR101326367B1 (ko) * | 2006-07-03 | 2013-11-11 | 가톨릭대학교 산학협력단 | 항암제 저항성의 진단 방법 및 진단 키트 |
| SG177956A1 (en) * | 2006-08-11 | 2012-02-28 | Baylor Res Inst | Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections |
| WO2008144011A1 (en) * | 2007-05-16 | 2008-11-27 | Avalon Pharmaceuticals | Compounds and methods for treating or preventing autoimmune diseases |
| US11466061B2 (en) | 2014-08-22 | 2022-10-11 | Yingfang Liu | Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the IFP35 family of proteins |
| JP7475366B2 (ja) | 2019-04-01 | 2024-04-26 | 広州恩邁生物科技有限公司 | 慢性炎症およびウイルス感染の診断と治療 |
-
2015
- 2015-08-21 US US15/505,600 patent/US11466061B2/en active Active
- 2015-08-21 EP EP15834006.7A patent/EP3182990A4/en active Pending
- 2015-08-21 JP JP2017510624A patent/JP6968696B2/ja active Active
- 2015-08-21 CN CN202210537590.6A patent/CN115054687A/zh active Pending
- 2015-08-21 WO PCT/CN2015/000602 patent/WO2016026258A1/en not_active Ceased
- 2015-08-21 CN CN201580045210.5A patent/CN107427552B/zh active Active
- 2015-08-21 CN CN202210537585.5A patent/CN114796497A/zh active Pending
-
2022
- 2022-09-08 US US17/930,635 patent/US20230265135A1/en active Pending
-
2024
- 2024-09-27 US US18/899,585 patent/US20250059242A1/en active Pending
- 2024-09-27 US US18/899,627 patent/US20250084137A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528129A5 (enExample) | ||
| JP2016020389A5 (enExample) | ||
| JP2013165711A5 (enExample) | ||
| JP2014524746A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| JP2016513664A5 (enExample) | ||
| JP2018531914A (ja) | ＣＤ１５５／ＴＩＧＩＴ経路およびＴＧＦ−βのアンタゴニストを介してがんを処置するための組成物および方法 | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| JP2013539468A5 (enExample) | ||
| JP2021517566A (ja) | 汎発性膿疱性乾癬の処置のための抗ｉｌ−３６ｒ抗体の使用 | |
| JP2016520520A5 (enExample) | ||
| JP2015506944A5 (enExample) | ||
| JP2014530244A5 (enExample) | ||
| WO2019023410A1 (en) | ANTI-TIM-1 ANTIBODIES AND USES THEREOF | |
| RU2663694C2 (ru) | Лечение злокачественных новообразований на основе стратификации по caix | |
| JP2019519475A (ja) | ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用 | |
| CN108473582A (zh) | 用于治疗纤维化和/或纤维化病症的抗－αV整合素抗体 | |
| JP2023115014A (ja) | 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体 | |
| CN112585164A (zh) | 用于治疗癌症的、lif抑制剂和pd-1轴抑制剂的组合 | |
| JP2021502344A (ja) | 腫瘍を処置する方法 | |
| JP2018509423A5 (enExample) | ||
| RU2020115161A (ru) | Днк моноклональных антител против ctla-4 для лечения и профилактики рака | |
| KR20200068746A (ko) | Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells) |